Day: May 13, 2020

MALVERN, Pa., May 13, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective analysis of Phase 2b trial data demonstrating the potential renal protective activity of lead candidate avasopasem manganese (GC4419), and two ongoing clinical trials evaluating avasopasem, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place May 29-31, 2020. Abstracts are available now in the ASCO digital program, and presentations will be available for on-demand viewing on May 29, 2020, at 8 a.m. EDT.“We look forward to sharing important clinical updates that...

Delray Beach, FL, May 13, 2020 (GLOBE NEWSWIRE) — Forum Merger II Corporation (Nasdaq: FMCI) (“Forum” or the “Company”) today announced it has signed a letter of intent and expects to sign a definitive agreement to acquire a high-growth, plant-based food company with a broad portfolio of innovative products that are aligned with major food trends and sold through leading retailers and distributors across the United States (the “Target”).The Target’s disruptive strategy is focused on addressing the growing consumer demand for nutritious, great tasting, better-for-you products with plant-based food. The Target’s alignment with today’s secular food trends, combined with its robust, plant-based offerings that feature unique ingredients, innovative recipes and creative branding, has allowed it to establish a meaningful market presence...

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced further details of oral and poster presentations at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 – May 31, 2020.Presentation titles, presenters and timing are listed below with all abstracts available at the ASCO20 Meeting Library.CytomX’s ASCO20 clinical presentations for CX-072 (Abstract 3005), CX-2009 (Abstract 526) as well as CX-2029 (Abstract 3502), developed in partnership with AbbVie, will have data cutoff dates of approximately five months later than the abstract...

GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update.“Throughout 2020 we have put significant effort into developing our pipeline; from advancing our vaccine candidates, AdCOVID and Nasoshield, to IND enabling studies and manufacturing for ALT-801 and HepTcell,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “Based on our progress, we are poised for a data-rich year, with the expected initiation of NasoShield, ALT-801 and AdCOVID clinical trials.”Recent HighlightsPreclinical testing commences on COVID-19 vaccine candidate, AdCOVIDIn collaboration with the University of Alabama at Birmingham (UAB), we have commenced preclinical testing of...

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, today announced the release of its financial results for the first quarter ended March 31, 2020.HIGHLIGHTSTotal sales of $872.7 million; production sales of $822.5 millionFirst quarter diluted net earnings per share of $0.36First quarter diluted adjusted net earnings per share(1) of $0.38Unfavourable impact of shutdowns related to COVID-19 in the quarterQuarterly free cash flow(1) of $9.9 millionBalance sheet ended the quarter strong; net debt(1):adjusted EBITDA(1) ratio (excluding impact of IFRS 16) of 1.62xCompany has taken aggressive cash conservation measuresCompany has...

CAMBRIDGE, Mass. and NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the design of MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place from May 29-31, 2020. The abstract, published in advance of the ASCO Annual Meeting, was made available at 5:00 PM ET today on the ASCO meeting website at https://meetinglibrary.asco.org/record/191686/abstract.Details of the abstract presentation are as follows:Abstract TPS3665Hamilton et al. Masterkey-01: Phase I/II,...

ACTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020. The Company’s revenue for the quarter ended March 31, 2020 was $7.5 million versus $9.8 million for the quarter ended March 31, 2019, a decrease of 23%.  Net loss for the quarter ended March 31, 2020 was $0.2 million or ($0.03) per diluted share, versus net income of $0.6 million or $0.11 per diluted share, for the comparable period last year, a decrease of $0.14 per diluted share.Raymond C. Kubacki, Chairman and Chief Executive Officer, stated:“As with many companies, first quarter revenues and earnings were negatively impacted by the coronavirus pandemic (“COVID-19”).   “While the impact from COVID-19 affected the Company’s sales volumes, it did not impact...

Amsterdam, The Netherlands, May 13, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces three abstracts supporting the potential of the Company’s K-NK cell therapy program to treat relapsed/refractory acute myeloid leukemia (R/R ML) have been accepted at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting taking place May 29 – 31, 2020.The ASCO abstracts are now available at https://meetings.asco.org/am/virtual-format. Details of the presentations are as follows:·  Abstract #3025 has been accepted as a poster and presents clinical data of a subset of R/R AML patients with CNS disease treated with FC21-NK cells in a phase I/II study (NCT02809092).Abstract DetailsTitle: CD56bright/CD16bright NK-cell adoptive immunotherapy...

Amsterdam, 13 mei 2020 – Kiadis Pharma N.V. (‘Kiadis Pharma’ of de ‘Onderneming’) (Euronext Amsterdam en Brussel: KDS), gaat drie presentatie houden op de (dit jaar virtuele) bijeenkomst van de  American Society of Clinical Oncology (ASCO), van 29 mei tot 31 mei 2 2020. De drie presentaties zijn gericht op het potentieel van het KNK-celtherapieprogramma voor de behandeling van terugkerende acute myeloïde leukemie (R/R ML).De volledige ASCO presentaties  zijn beschikbaar op www.asco.org. Hier volgen nadere gegevens van de presentaties:·  Abstract 3025 is geaccepteerd als posterpresentatie en toont de klinische gegevens van een subset van R/R AML-patiënten met CNS-ziekte, die behandeld zijn met FC21-NK cellen in een fase I/II-studie (NCT02809092).Details van de presentatieTitel: ‘CD56bright/CD16bright NK-cell adoptive immunotherapy in patients...

BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference. The fireside chat is scheduled to begin at 10:55 a.m. ET on Tuesday, May 19, 2020.To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity,...